If the recent CMS rescinding of the MCIT rule has reminded us of anything, it’s that the medtech landscape is constantly shifting and building a strategy on an ever-changing policy landscape is not for the faint of heart. When our CEO was a recent guest on Life Science Success podcast and was asked what her biggest concern was, her answer was policy.
As we’ve heard our CEO, Dr. April Zambelli-Weiner, talk about before, a market access plan should be 3 things:
Flexible includes having experts who regularly monitor and revisit the policy landscape to incorporate new information and changing market dynamics into your plan.
Not having a handle on the shifting policy landscape could mean you waste precious time and resources going down the wrong path (at best). At worst, a misstep could not just mean the end of your company, you could be facing civil and criminal charges. Products with laboratory testing components are at particular risk.